Identity and exposure
TB-500 and thymosin beta-4 research
The fragment’s identity, the parent protein’s experiments, and the human exposure record that a safety claim has to survive.
Thymosin beta-4 and the LKKTETQ fragment
The identity problem is concrete. Thymosin beta-4 is a 43-amino-acid protein found throughout the body. TB-500 is the synthetic Ac-LKKTETQ fragment corresponding to residues 17–23. The TB-500 detection paper describes the acetylated fragment itself; the thymosin beta-4 review follows the larger protein’s repair biology. Those are overlapping subjects with different experimental records.
Full thymosin beta-4 can also yield Ac-SDKP, a separate cleavage product associated with anti-fibrotic and angiogenic activity. The TB-500 fragment cannot generate that piece. Treating the larger molecule as a sack of interchangeable benefits is an extrapolation I cannot accept: removing most of its sequence leaves a new question about what survives.
Actin sequestration
Actin gives a cell structure and helps it move. Sequestration means holding free actin in reserve, controlling how much is available to join into filaments. In the Irobi structural study, a gelsolin-domain-1–thymosin beta-4 hybrid bound actin in a 1:1 complex. The X-ray structure resolved detail at 2 Å and showed capping at both ends of the actin monomer, preventing polymerization.
That is unusually satisfying evidence for a molecular grip. I trust its precision within that experimental setup. The next step—whether isolated TB-500 produces useful repair in a person—requires a different experiment. A detailed structure gives the mechanism a foundation; clinical efficacy remains open.
Wound repair and inflammation
In the rat full-thickness wound experiment, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at four days and up to 61% at seven days versus saline. Wound contraction increased by at least 11% by day seven, with greater collagen deposition and angiogenesis. In a cell assay, as little as 10 pg stimulated keratinocyte migration two to three times more.
The repair argument extends beyond simply getting cells to move. Qiu and colleagues measured increased matrix metalloproteinase expression during wound repair; those enzymes help remodel the material around cells. The review of thymosin beta-4 biology also describes fewer myofibroblasts, the cells associated with scarring, and anti-inflammatory activity. These are animal and cell findings concerning the full protein. I give them credit as a coherent research rationale, while leaving human TB-500 recovery unanswered.
Angiogenesis and tumor research
Angiogenesis is the growth of new blood vessels. In cell work, full thymosin beta-4 increased VEGF expression through a HIF-1α-dependent mechanism. VEGF is a vessel-growth signal; HIF-1α is involved in the response to low oxygen. Vessel-wall cells also moved. Those observations help explain the interest in supplying injured tissue with blood.
They also explain why the safety discussion cannot stop at healing. Tumor-model research implicated thymosin beta-4 in metastasis and angiogenesis, and human pancreatic cancer cells showed elevated thymosin beta-4 and altered signaling. These experiments raise a plausible concern about tumor progression. They establish no measured cancer rate for people exposed to TB-500. A blanket safety claim asks me to overlook that unresolved question. A claim that the fragment has been shown to cause cancer also exceeds these findings.
Human exposure data and the FDA concern
The randomized, placebo-controlled Phase 1 study enrolled 40 healthy volunteers and administered synthetic full-length thymosin beta-4 intravenously. The amounts were 42, 140, 420, and 1260 milligrams, in single-dose and daily-for-14-days testing. Adverse events were infrequent and mild or moderate; there were no dose-limiting toxicities or serious adverse events. Half-life increased with dose.
I welcome that result, including its reassuring observations. The exposure was to the parent protein through a vein. It leaves the fragment’s longer-term safety, other administration routes and clinical benefit unresolved. Other human work in the record concerns topical ophthalmic thymosin beta-4.
On FDA’s page current as of April 22, 2026, the entry for thymosin beta-4 fragment (LKKTETQ), also known as TB-500, sits in the withdrawn-nomination table. FDA’s recorded concerns include immunogenicity with certain routes and insufficient safety information. Withdrawal preserves those concerns and grants neither approval nor Category 1 placement. The FDA and compounding page explains the administrative sequence.
Heart trials on ClinicalTrials.gov
The ClinicalTrials.gov record for NCT01311518 concerns injectable thymosin beta-4 for acute myocardial infarction, a heart attack. It was withdrawn before it began, with enrollment 0. I count that listing as evidence of a plan that stopped. It supplies no treated participants and no treatment outcome.
Animal heart findings are mixed too. Mouse work found improved early heart-cell survival and cardiac function after coronary artery ligation. The existing animal-study record also includes a porcine ischemia-reperfusion failure: systemic thymosin beta-4 did not reduce that injury. Different species and injury models need careful comparison. Together, these findings leave plenty of experimental work to do before a human TB-500 heart claim can carry much weight.